Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of ACT-128800 in Patients With Relapsing-remitting Multiple Sclerosis

Status:
Completed

Trial end date:
2011-07-01

Target enrollment:

Participant gender:

This study will assess the efficacy, safety, and tolerability of ACT-128800 in patients with relapsing-remitting multiple sclerosis.

Phase 2

Actelion

Ponesimod